跳至主要內容

新聞與行事曆

新聞: 截至 2026-10-12
這些標記是什麼意思

重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。

已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。

標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。

經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。

涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。

閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。

未來

已排定 · 今天與明天 · 行事曆更新於 2026-10-13

10月13日週二 · 今天

10月14日週三

過往

已發布 · 最新在前

9月18日週五

產品

17:54
PR Newswire

U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

The FDA granted full approval to Lilly's oral ER antagonist Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The approval is based on the Phase 3 EMBER-3 trial.

文章預覽

Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free survival compared to Inluriyo alone, among patients with ESR1 -mutated MBC The all-oral combination of Inluriyo and Verzenio gives patients a treatment approach that targets the two central drivers of ER+ breast cancer, with an established tolerability profile and no new monitoring required INDIANAPOLIS , Sept. 1…

Eli Lilly and Company 開啟原文 ↗

合作

16:02
NASA

NASA Awards SpaceX Three Crew Flights to Space Station

NASA awarded SpaceX three additional space station crew missions (Crew-15, Crew-16 and Crew-17) through a $946 million modification to its Commercial Crew Transportation Capability contract, bringing SpaceX's total to 17 missions and the total contract value with SpaceX to $5.92 billion.

文章預覽

2 min read NASA Awards SpaceX Three Crew Flights to Space Station Mark A. Garcia Sep 18, 2026 Article A SpaceX Falcon 9 rocket carrying the company’s Dragon spacecraft launches NASA’s SpaceX Crew-10 mission to the International Space Station on March 14, 2025. NASA/Aubrey Gemignani Editor’s note: This feature was updated on Sept. 18, 2026, to add additional details on mission readiness dates. To continue regular crew transportation to the International Space Station, NASA has awarded SpaceX three additional missions through a contract modification. As part of the agency’s Commercial Crew…

Space Exploration Technologies Corp. (SpaceX) 開啟原文 ↗

監管

13:35
JUVE Patent

EPO revokes key Moderna patent for mRNA vaccines

The EPO Boards of Appeal revoked Moderna's European patent EP 3 590 949, the key mRNA vaccine patent on which Moderna had brought legal action against BioNTech and Pfizer. The decision nullifies Moderna's earlier wins before national courts in London and Düsseldorf, though litigation between the parties is likely to continue.

文章預覽

From Europe. For the global patent community. Trending Topics: Dutch patent market Patent market moves UK patent market Unified Patent Court JUVE Patent People & Business EPO revokes key Moderna patent for mRNA vaccines mRNA technology EPO revokes key Moderna patent for mRNA vaccines The legal dispute between Moderna, BioNTech and Pfizer has taken a new turn. Following Moderna's recent successes at the national courts in Düsseldorf and London, the EPO Boards of Appeal have completely revoked the key patent at the heart of the dispute. Nevertheless, this decision is likely to be merely the end…

ModernaPfizer 開啟原文 ↗

融資

11:00
CoreWeave

CoreWeave Prices Upsized $3.7 Billion Convertible Senior Notes Offering

CoreWeave priced an upsized private offering of $3.7 billion of 2.875% convertible senior notes due 2033, up from the previously announced $3.0 billion, with settlement scheduled for September 22, 2026. The initial conversion price is approximately $97.85 per share.

CoreWeave 開啟原文 ↗

合作

05:59
SK hynix Newsroom

SK hynix Launches 'SK hynix Ventures' in Silicon Valley to Expand Global AI Ecosystem Investment

SK hynix announced the launch of its corporate venture capital brand, SK hynix Ventures, and held an inaugural Ventures Day in Silicon Valley attended by CEO Kwak Noh-Jung. Through it, the company plans to broaden its investment scope from traditional semiconductors and emerging tech to AI computing, data centers, system software and optical interconnect; no investment amount was disclosed.

文章預覽

PRESS SK hynix Launches ‘SK hynix Ventures’ in Silicon Valley to Expand Global AI Ecosystem Investment ▪ CEO Kwak Noh-Jung and key executives, alongside global VCs and startup leaders, attend the inaugural ‘SK hynix Ventures Day’ in Silicon Valley ▪ Company to expand investments across the entire AI ecosystem ▪ Discussing strategies to strengthen partnerships with global venture firms and investors in future technology fields such as AI data centers and optical-based systems Seoul, September 18, 2026 – SK hynix Inc. (or “the company”, www.skhynix.com ) announced today the launch of its corpora…

SK Hynix 開啟原文 ↗

原始消息流

所有到達的消息 · 7 天